CA2419047A1 - Water-soluble prodrugs of propofol for treatment of migraine - Google Patents

Water-soluble prodrugs of propofol for treatment of migraine Download PDF

Info

Publication number
CA2419047A1
CA2419047A1 CA002419047A CA2419047A CA2419047A1 CA 2419047 A1 CA2419047 A1 CA 2419047A1 CA 002419047 A CA002419047 A CA 002419047A CA 2419047 A CA2419047 A CA 2419047A CA 2419047 A1 CA2419047 A1 CA 2419047A1
Authority
CA
Canada
Prior art keywords
propofol
migraine
water
pharmaceutically acceptable
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419047A
Other languages
English (en)
French (fr)
Inventor
Sheldon S. Hendler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
374Water Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2419047A1 publication Critical patent/CA2419047A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002419047A 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine Abandoned CA2419047A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/639,015 2000-08-15
US09/639,015 US6362234B1 (en) 2000-08-15 2000-08-15 Water-soluble prodrugs of propofol for treatment of migrane
PCT/US2001/025540 WO2002013810A1 (en) 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine

Publications (1)

Publication Number Publication Date
CA2419047A1 true CA2419047A1 (en) 2002-02-21

Family

ID=24562380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419047A Abandoned CA2419047A1 (en) 2000-08-15 2001-08-14 Water-soluble prodrugs of propofol for treatment of migraine

Country Status (5)

Country Link
US (1) US6362234B1 (enExample)
EP (1) EP1318798A4 (enExample)
JP (1) JP2004517810A (enExample)
CA (1) CA2419047A1 (enExample)
WO (1) WO2002013810A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
UA76802C2 (uk) * 2001-12-28 2006-09-15 Мгі Гп, Інк. Фармацевтичний препарат водорозчинних проліків пропофолу на водній основі (варіанти)
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
IL164217A0 (en) * 2002-04-08 2005-12-18 Guilford Pharm Inc Pharmaceutical compositions containing water-soluble propofol and methods of administering same
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE20215415U1 (de) * 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
WO2005023204A2 (en) * 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
EP1680409A4 (en) * 2003-10-24 2007-12-05 Auspex Pharmaceuticals Inc PH-SENSITIVE 2,6-DIISOPROPYLPHENOL PROMEDICAMENTS
WO2005058250A2 (en) * 2003-12-17 2005-06-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol for extended sedation
DK1781596T3 (da) * 2004-07-12 2009-01-19 Xenoport Inc Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1791521A4 (en) * 2004-09-17 2009-10-21 Eisai Corp North America METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE
WO2006071995A1 (en) * 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
WO2007028104A2 (en) * 2005-09-02 2007-03-08 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
US8173849B2 (en) 2007-05-09 2012-05-08 Signature Therapeutics, Inc. Therapeutic compounds
JP5651009B2 (ja) 2007-05-09 2015-01-07 ソウッド ヘルスケア エルエルシー 治療用化合物
WO2008157627A1 (en) * 2007-06-21 2008-12-24 Xenoport, Inc. Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus
US20090076141A1 (en) * 2007-09-14 2009-03-19 Xenoport, Inc. Use of Propofol Prodrugs for Treating Neuropathic Pain
GB0905834D0 (en) 2009-04-03 2009-05-20 Seps Pharma Nv Phosphonyl-containing phenolic derivatives useful as medicaments
CN101575349B (zh) * 2009-06-11 2011-07-20 中国科学院广州化学研究所 一种丙泊酚磷酸酯二钠盐的制备方法
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5399944B2 (ja) * 2010-02-25 2014-01-29 信越化学工業株式会社 リン酸エステル基含有オルガノポリシロキサンの製造方法
JP5502540B2 (ja) * 2010-03-19 2014-05-28 信越化学工業株式会社 リン酸エステル基含有オルガノポリシロキサンの製造方法
CN102821791B (zh) 2010-03-30 2015-06-17 磷肌酸有限公司 透皮递送贴剂
CN101885735B (zh) * 2010-06-23 2012-09-12 四川大学华西医院 取代苯酚羟基酸酯的磷酸酯化合物、制备方法及在药物中的应用
WO2011161687A1 (en) 2010-06-23 2011-12-29 Harman Finochem Limited Process for preparing extra pure 2, 6-diisopropyl phenol
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINOCHINOLINE AS A KINASEHEMMER
CN102260184B (zh) * 2011-06-09 2014-07-02 浙江九旭药业有限公司 丙泊酚衍生物及其制备方法和应用
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
WO2017205632A1 (en) * 2016-05-27 2017-11-30 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
US20190330260A1 (en) 2016-12-21 2019-10-31 Avecho Biotechnology Limited Process
US11547714B2 (en) 2020-02-05 2023-01-10 Epalex Corporation Fospropofol salts, methods and compositions
US11628178B2 (en) 2019-03-26 2023-04-18 Epalex Corporation Fospropofol methods and compositions
US11478490B1 (en) 2021-03-30 2022-10-25 Epalex Corporation Fospropofol formulations
US11439653B1 (en) 2021-03-30 2022-09-13 Epalex Corporation Fospropofol formulations
CN112694414B (zh) 2019-10-22 2023-02-28 四川大学华西医院 一类取代苯酚羟基酸酯含n衍生物、制备和用途
EP3912621A1 (en) * 2020-05-19 2021-11-24 tesa Labtec GmbH Propofol for diagnosis of primary headache

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
JPH08339002A (ja) * 1995-04-10 1996-12-24 Ngk Insulators Ltd 第二高調波発生素子およびその製造方法
US5891875A (en) * 1996-05-20 1999-04-06 Eli Lilly And Company Morpholinyl tachykinin receptor antagonists
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols

Also Published As

Publication number Publication date
EP1318798A1 (en) 2003-06-18
WO2002013810A1 (en) 2002-02-21
US6362234B1 (en) 2002-03-26
JP2004517810A (ja) 2004-06-17
EP1318798A4 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
US6362234B1 (en) Water-soluble prodrugs of propofol for treatment of migrane
US6254853B1 (en) Water soluble pro-drugs of propofol
KR100400075B1 (ko) 세포로의침투가개선된약제
US5284867A (en) NMDA-blocking pharmaceutical compositions
US20130225529A1 (en) Phospho-ester derivatives and uses thereof
US20140178461A1 (en) Compounds and compositions for use in the treatment and prevention of lung and brain cancer and precancerous conditions thereof
US20120329765A1 (en) Medicinal targeted local lipolysis
JPWO1991010431A1 (ja) 脂肪乳剤
EP1515711A1 (en) Pharmaceutical composition
US12102616B2 (en) Psilocin mucate
JP3036881B2 (ja) ビロバリデ誘導体、この用途及びこれを含有する薬剤組成物
PT1771155E (pt) Método e composição para o tratamento da rinite
US20110086820A1 (en) Analgesic agent comprising cyclic phosphatidic acid derivative
WO1999024400A1 (en) Probucol esters and uses thereof
WO2011135020A1 (de) Verwendung einer phospholipid und glycyrrhizinsäure enthaltenden zusammensetzung zur entfernung von subkutanen fettansammlungen durch subkutane lipolyse
JPS637526B2 (enExample)
EP0661053A1 (en) Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases
EP1419129B1 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
EP0166436A2 (en) Use of dolichol or its ester in medicines
AU2283000A (en) Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
KR950005914B1 (ko) Nmda-차단 제약조성물
JP2002524016A (ja) イノシトールポリホスフェート誘導体およびその使用方法
US7582678B2 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
KR100187652B1 (ko) 지방성 유화액

Legal Events

Date Code Title Description
FZDE Discontinued